(Q57759687)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

0 references

0 references

1 reference

1 reference

1 reference

1 reference

María A Nuñez-Sánchez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Rocio Garcia Villalba

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Antonio González-Sarrías

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

Francisco A Tomas-Barberan

8 March 2020

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Juan Carlos Espín

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Tamara Monedero-Saiz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Carmen Sánchez-Álvarez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Miguel Ruiz-Marín

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Francisco Martínez-Díaz

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Noelia V García-Talavera

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

María B Gómez-Sánchez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ana M García-Albert

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Francisco J Rodríguez-Gil

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Francisco A Pastor-Quirante

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

María J Yáñez-Gascón

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

16 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

Molecular Nutrition and Food Research

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

1199-1211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

The bioactivity of pomegranate: impact on health and disease.

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Ellagitannins, ellagic acid and vascular health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Inhibitory effect of a standardized pomegranate fruit extract on Wnt signalling in 1, 2-dimethylhydrazine induced rat colon carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrant crypt foci and inflammation: possible role of miR-126/VCAM-1 and miR-126/PI3K/AKT/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Time course production of urolithins from ellagic acid by human gut microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

NF-kappaB-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Metabolites and tissue distribution of resveratrol in the pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Effects of fruit ellagitannin extracts, ellagic acid, and their colonic metabolite, urolithin A, on Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Urolithins display both antioxidant and pro-oxidant activities depending on assay system and conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Central administration of resveratrol improves diet-induced diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

Has the risk of colorectal cancer in inflammatory bowel disease decreased?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMNFR.201300931

21 January 2018

Identifiers

DOI

10.1002/MNFR.201300931

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24532260%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference